2. Disease Areas
  3. Cancer Respiratory Disease
  4. Lung Cancer Respiratory Cancer
  5. Lung Squamous Cell Carcinoma

Lung Squamous Cell Carcinoma

Lung squamous cell carcinoma, also known as epidermoid carcinoma, is a type of non-small-cell lung cancer that arises from the thin, flat cells lining the airways, accounting for approximately 30% of all lung cancers. It typically develops in the central air passages of the lungs and is one of the major subtypes of non-small-cell lung cancer, alongside adenocarcinoma and large cell carcinoma. While early stages may be asymptomatic, common symptoms include coughing, chest pain, weight loss, and fatigue; if the cancer spreads beyond the lungs, it may cause difficulty swallowing or shortness of breath. Non-small-cell lung cancers represent about 85% of all lung cancer cases, highlighting the significance of squamous cell carcinoma within this group.

Lung Squamous Cell Carcinoma (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17394
    Cisplatin 15663-27-1 99.84%
    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy.
    Cisplatin
  • HY-B0015
    Paclitaxel 33069-62-4 99.97%
    Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.
    Paclitaxel